Horizon Therapeutics Public (NASDAQ:HZNP) and Bausch Health Companies (NYSE:BHC) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.
Profitability
This table compares Horizon Therapeutics Public and Bausch Health Companies' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Horizon Therapeutics Public | 43.55% | 25.66% | 14.19% |
Bausch Health Companies | -23.92% | 173.20% | 4.21% |
Earnings & Valuation
This table compares Horizon Therapeutics Public and Bausch Health Companies' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Horizon Therapeutics Public | $1.30 billion | 15.38 | $573.02 million | $1.94 | 46.69 |
Bausch Health Companies | $8.60 billion | 1.29 | $-1,788,000,000.00 | $4.43 | 7.06 |
Horizon Therapeutics Public has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Horizon Therapeutics Public has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Horizon Therapeutics Public and Bausch Health Companies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Horizon Therapeutics Public | 0 | 0 | 8 | 0 | 3.00 |
Bausch Health Companies | 0 | 5 | 7 | 0 | 2.58 |
Horizon Therapeutics Public presently has a consensus price target of $101.8889, indicating a potential upside of 12.50%. Bausch Health Companies has a consensus price target of $30.1818, indicating a potential downside of 3.51%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, research analysts clearly believe Horizon Therapeutics Public is more favorable than Bausch Health Companies.
Insider & Institutional Ownership
88.6% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Horizon Therapeutics Public beats Bausch Health Companies on 9 of the 14 factors compared between the two stocks.